SAB Biotherapeutics, Inc.

NASDAQ:SABS

2.79 (USD) • At close September 13, 2024
Bedrijfsnaam SAB Biotherapeutics, Inc.
Symbool SABS
Munteenheid USD
Prijs 2.79
Beurswaarde 25,749,663
Dividendpercentage 0%
52-weken bereik 2.16 - 10.5
Industrie Biotechnology
Sector Healthcare
CEO Dr. Eddie Joe Sullivan Ph.D.
Website https://www.sabbiotherapeutics.com

An error occurred while fetching data.

Over SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune

Vergelijkbare Aandelen

Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc.

ASMB

18.07 USD

Lipocine Inc. logo

Lipocine Inc.

LPCN

4.61 USD

aTyr Pharma, Inc. logo

aTyr Pharma, Inc.

LIFE

1.9 USD

Wave Life Sciences Ltd. logo

Wave Life Sciences Ltd.

WVE

5.86 USD

Vigil Neuroscience, Inc. logo

Vigil Neuroscience, Inc.

VIGL

3.67 USD

Miromatrix Medical Inc. logo

Miromatrix Medical Inc.

MIRO

3.39 USD

BioAtla, Inc. logo

BioAtla, Inc.

BCAB

1.81 USD

Clearside Biomedical, Inc. logo

Clearside Biomedical, Inc.

CLSD

1.23 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)